ArticlemedRxiv : the preprint server for health sciences2024
Genome-wide Polygenic Risk Scores Predict Risk of Glioma and Molecular Subtypes.
Taishi Nakase, Geno Guerra, Quinn T Ostrom, Tian Ge, Beatrice Melin, Margaret Wrensch, John K Wiencke, Robert B Jenkins, Jeanette E Eckel-Passow, Glioma International Case-Control Study (GICC) and 3 more
Open access · greenAbstract readPreprint
In one paragraphArticle in medRxiv : the preprint server for health sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed, 1 citations in OpenAlex.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
5 · Who and what moneyAuthors and funding
13 authors at 7 institutions in 2 countries.
Taishi NakaseDepartment of Epidemiology & Population Health, Stanford University School of Medicine, Stanford, CA, USA.ORCID 0000-0002-3078-098X Geno GuerraDepartment of Neurological Surgery, University of California San Francisco, San Francisco, CA, USA.ORCID 0000-0001-9870-9998 Tian GePsychiatric and Neurodevelopmental Genetics Unit, Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA, USA.ORCID 0000-0003-4785-4444 Margaret WrenschDepartment of Neurological Surgery, University of California San Francisco, San Francisco, CA, USA.
John K WienckeDepartment of Neurological Surgery, University of California San Francisco, San Francisco, CA, USA.
Robert B JenkinsDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
Jeanette E Eckel-PassowDivision of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN, USA.
Glioma International Case-Control Study (GICC)
Melissa L BondyDepartment of Epidemiology & Population Health, Stanford University School of Medicine, Stanford, CA, USA.ORCID 0000-0002-0278-414X Stephen S FrancisDepartment of Neurological Surgery, University of California San Francisco, San Francisco, CA, USA.ORCID 0000-0002-6488-6272 Linda KachuriDepartment of Epidemiology & Population Health, Stanford University School of Medicine, Stanford, CA, USA.ORCID 0000-0002-3226-4727 University of California, San Francisco · USStanford University · USBroad Institute · USDuke University · USMayo Clinic · USMayo Clinic in Arizona · USUmeå University · SE
Funding
UCSF CLINICAL AND TRANSLATIONAL SCIENCE INSTITUTEUL1RR024131 · NCRR · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI JOHNSTON, S. CLAIBORNE · 2006 to 2011
$111.2MTissue CoreP50CA097257 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Susan M Chang · 2002 to 2026
$57.4MTargeted MV-CEA as a Potent Antitumor Agent against GBMP50CA108961 · NCI · MAYO CLINIC ROCHESTER · PI O'NEILL, BRIAN PATRICK · 2004 to 2015
$22.5MGENETIC EPIDEMIOLOGY OF MALIGNANT GLIOMAR01CA052689 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI WIENCKE, JOHN K., WRENSCH, MARGARET R. · 1991 to 2015
$20.5MInternational Case Control Study of Malignant GliomaR01CA139020 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI BONDY, MELISSA L. · 2010 to 2015
$16.0MTraining Program in Translational Brain Tumor ResearchT32CA151022 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Joseph F Costello · 2010 to 2026
$6.6MTraining in Molecular& Genetic Epidemiology of CancerR25CA112355 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI WITTE, JOHN S. · 2005 to 2018
$6.5MIntegrated Exchange and Storage of Current- and Future-Generation Immunogenomic DataR01AI128775 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI JILL Allison HOLLENBACH, STEVEN JOHN MACK · 2017 to 2026
$4.5MUNDERSTANDING THE INTERACTIONS BETWEEN GERMLINE AND SOMATIC ALTERATIONS in the PATHOGENESIS OF GLIOMASR01CA230712 · NCI · MAYO CLINIC ROCHESTER · PI JENKINS, ROBERT B. · 2018 to 2022
$3.3MBiomarkers of survival in glioma epidemiologyR01CA126831 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI WIENCKE, JOHN K. · 2008 to 2013
$2.5MComprehensive Investigation of Multiple Myeloma Genetic Susceptibility in African AmericansR00CA246076 · NCI · STANFORD UNIVERSITY · PI KACHURI, MIRLINDA · 2022 to 2024
$747kNCCDPHP CDC HHS NU58DP006344NCI NIH HHS HHSN261201800009CNCI NIH HHS HHSN261201800009INCI NIH HHS HHSN261201800015CNCI NIH HHS HHSN261201800015INCI NIH HHS HHSN261201800032CNCI NIH HHS HHSN261201800032INCI NIH HHS P50 CA097257NCI NIH HHS P50 CA108961NCI NIH HHS R00 CA246076NCI NIH HHS R01 CA052689NCI NIH HHS R01 CA126831NCI NIH HHS R01 CA139020NCI NIH HHS R01 CA230712NCI NIH HHS R25 CA112355NCI NIH HHS T32 CA151022NCRR NIH HHS UL1 RR024131NIAID NIH HHS R01 AI128775
6 · The paper itselfAbstract
Background: Polygenic risk scores (PRS) aggregate the contribution of many risk variants to provide a personalized genetic susceptibility profile. Since sample sizes of glioma genome-wide association studies (GWAS) remain modest, there is a need to find efficient ways of capturing genetic risk factors using available germline data. Methods: We developed a novel PRS (PRS-CS) that uses continuous shrinkage priors to model the joint effects of over 1 million polymorphisms on disease risk and compared it to an approach (PRS-CT) that selects a limited set of independent variants that reach genome-wide significance (P<5×10 Results: PRS-CS was consistently more predictive than PRS-CT across glioma subtypes with an average increase in explained variance (R Conclusions: Our novel genome-wide PRS may improve the identification of high-risk individuals and help distinguish between prognostic glioma subtypes, increasing the potential clinical utility of germline genetics in glioma patient management.
Indexed as
genetic susceptibilitygliomaPolygenic risk score (PRS)predictionrisk
Identifiers
PMID38260701
PMCPMC10802631
OpenAlexW4390740015
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390